Zhu Hong, Yang Xi, Zhao Yaqin, Yi Cheng
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China.
Medicine (Baltimore). 2019 May;98(20):e15755. doi: 10.1097/MD.0000000000015755.
Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is an aggressive tumor with very poor prognosis. Regorafenib was the first agent to show a survival benefit over placebo in patients who showed progression while being treated with sorafenib, but it remains an unsatisfactory agent owing to its serious side effects. Therefore, more efficient and milder therapies are needed.
Herein, we report a patient with advanced HCC with many lung metastases who showed progression during sorafenib treatment.
HCC with lung metastases (stage IVB).
SHR-1210 alone was used as second-line treatment.
Although the lung metastases did not decrease 3 months after the treatment, they decreased significantly at 6 months after the treatment and partially disappeared. The tumor response indicated partial response. Furthermore, all of the lung metastases continued to decrease at about 17 months after treatment. The alpha-fetoprotein levels showed a similar trend. After a follow up of 19 months, the patient remains in good health.
SHR-1210 alone as a second-line treatment for a patient with HCC showed excellent antitumor effects. We think that SHR-1210 may exert its antitumor effects through a late-onset model, which persist for a long time. The side effects were mild and well tolerated.
肝细胞癌（HCC）是全球最常见的癌症之一，是一种侵袭性肿瘤，预后很差。瑞戈非尼是首个在接受索拉非尼治疗期间出现进展的患者中显示出比安慰剂更具生存获益的药物，但由于其严重的副作用，它仍然是一种不尽人意的药物。因此，需要更有效且更温和的治疗方法。
在此，我们报告一名患有晚期HCC且有多处肺转移的患者，该患者在索拉非尼治疗期间出现进展。
伴有肺转移的HCC（IVB期）。
单独使用SHR-1210作为二线治疗。
尽管治疗3个月后肺转移灶没有减少，但在治疗6个月时显著减少且部分消失。肿瘤反应显示为部分缓解。此外，在治疗约17个月时，所有肺转移灶持续减少。甲胎蛋白水平呈现类似趋势。经过19个月的随访，患者健康状况良好。
单独使用SHR-1210作为HCC患者的二线治疗显示出优异的抗肿瘤效果。我们认为SHR-1210可能通过一种起效较晚但持续时间长的模式发挥其抗肿瘤作用。副作用轻微且耐受性良好。
